Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | XIAP | P98170 | 1/20 | 0.62 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.62 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.57 |
| ▸ | LAP3 | P28838 | 7/20 | 0.56 |
| ▸ | ANPEP | P15144 | 2/20 | 0.56 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.56 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 2/20 | 0.55 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | CPA3 | P15088 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7415433 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL244193 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7436847 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL7698421 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL5491058 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL2201323 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL650855 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL3841332 | 1.00 | ALPI (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL1309497 | 0.98 | ALPI (0.60) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Hydrochloric Acid SCHEMBL3688220 | 0.98 | ALPI (0.60) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115784918-B | Preparation method of high-purity ubenimex intermediate | 四川青木制药有限公司 | 2024-10-15 | — | — | CN | claimed |
| US-12054502-B2 | Multifunctional immunity-targeted micromolecule anti-cancer medicine Bestazomib (Bestazomib) and preparation method and application thereof | SHANDONG HUBBLE KISEN BIOLOGICAL TECHNONLOGY CO., LTD. (CN) | 2024-08-06 | — | — | US | claimed |
| EP-3835305-B1 | MULTIFUNCTIONAL IMMUNITY-TARGETED MICROMOLECULE ANTI-CANCER MEDICINE BESTAZOMIB (BESTAZOMIB) AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGDONG HUBBLE KISEN BIOLOGICAL TECH CO LTD (CN) | 2023-10-04 | — | — | EP | claimed |
| CN-115784918-A | Preparation method of high-purity ubenimex intermediate | 四川青木制药有限公司 | 2023-03-14 | — | — | CN | claimed |
| US-20210300949-A1 | MULTIFUNCTIONAL IMMUNITY-TARGETED MICROMOLECULE ANTI-CANCER MEDICINE BESTAZOMIB (BESTAZOMIB) AND PREPARATION METHOD AND APPLICATION THEREOF | SHANDONG HUBBLE KISEN BIOLOGICAL TECHNOLOGY CO., LTD. (CN) | 2021-09-30 | — | — | US | claimed |
| CN-109115913-B | HPLC method for separating ramosetron hydrochloride and S-type enantiomer thereof based on conventional phenyl chromatographic column | 济南迪安医学检验中心有限公司 | 2021-08-06 | — | — | CN | claimed |
| EP-3835305-A1 | MULTIFUNCTIONAL IMMUNITY-TARGETED MICROMOLECULE ANTI-CANCER MEDICINE BESTAZOMIB (BESTAZOMIB) AND PREPARATION METHOD AND APPLICATION THEREOF | Shangdong Hubble Kisen Biological Technology Co., Ltd. (CN) | 2021-06-16 | — | — | EP | claimed |
| CN-109053782-B | Multifunctional targeting immune micromolecule anticancer drug Bestazomib citrate and preparation method and application thereof | 潍坊博创国际生物医药研究院 | 2020-01-17 | — | — | CN | claimed |
| EP-0156279-B1 | A NOVEL PROCESS FOR THE PREPARATION OF BESTATIN DERIVATIVES AND INTERMEDIATES THEREOF | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 1989-09-13 | — | — | EP | claimed |
| US-4179573-A | (2S,3R)-3-amino-2-hydroxy-4-phenylbutanoic acid | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1979-12-18 | — | — | US | claimed |
| JP-2017165-A | — | — | None | — | — | JP | disclosed |
| JP-55072151-A | — | — | None | — | — | JP | disclosed |
| EP-4702005-A1 | CNDP2 MODULATORS AND METHODS FOR THEIR USE | Metabolon Inc. (US) | 2026-03-04 | — | — | EP | disclosed |
| CN-120866438-A | Method for preparing ubenimex by enzymatic method | 华南理工大学 | 2025-10-31 | — | — | CN | disclosed |
| US-20250120927-A1 | CNDP2 MODULATORS AND METHODS FOR THEIR USE | METABOLON INC. | 2025-04-17 | — | — | US | disclosed |
| US-4179573-A | (2S,3R)-3-amino-2-hydroxy-4-phenylbutanoic acid | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1979-12-18 | — | — | US | disclosed |
| US-4179573-A | (2S,3R)-3-amino-2-hydroxy-4-phenylbutanoic acid | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1979-12-18 | — | — | US | disclosed |
| US-4179573-A | (2S,3R)-3-amino-2-hydroxy-4-phenylbutanoic acid | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1979-12-18 | — | — | US | disclosed |
| US-4052449-A | BIOLOGICALLY ACTIVE SUBSTANCE, BESTATIN, AND PRODUCTION THEREOF | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1977-10-04 | — | — | US | disclosed |
| US-4029547-A | Biologically active substance, bestatin, and production thereof | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054502-B2 | Multifunctional immunity-targeted micromolecule anti-cancer medicine Bestazomib (Bestazomib) and preparation method and application thereof | PSMA3, IL1RN, DPP3 | ALPI 418/4885PKM 459/4885PTGS1 4245/4885 |
| US-20250120927-A1 | CNDP2 MODULATORS AND METHODS FOR THEIR USE | CNDP2, DPP7, DPEP1 | ALPI 1366/4885PKM 2914/4885PTGS1 2452/4885 |
| US-20210300949-A1 | MULTIFUNCTIONAL IMMUNITY-TARGETED MICROMOLECULE ANTI-CANCER MEDICINE BESTAZOMIB (BESTAZOMIB) AND PREPARATION METHOD AND APPLICATION THEREOF | PSMA3, IL1RN, DPP3 | ALPI 418/4885PKM 459/4885PTGS1 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.